The Leukemia & Lymphoma Society, The Mark Foundation for Cancer Research and The Paul G. Allen Frontiers Group Partner to Award $6.75M in New Grants to Drive the Next Wave of Novel Cancer Therapies

On July 1, 2020 Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group reported more than $6.75 million awarded to nine of the most exceptional scientists in the field (Press release, The Leukemia & Lymphoma Society, JUL 1, 2020, View Source;lymphoma-society-the-mark-foundation-for-cancer-research-and-the-paul-g-allen-frontiers-group-partner-to-award-6-75m-in-new-grants-to-drive-the-next-wave-of-novel-cancer-therapies-301086643.html [SID1234561635]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The innovative Blood Cancer Discoveries Grant Program is designed to encourage researchers with deep experience in the blood cancers to conduct critical basic research in hopes of unleashing the next wave of novel approaches to treating leukemia, lymphoma, myeloma and myelodysplastic syndromes; together, these cancers are the 2nd leading cause of cancer deaths in the U.S.

"Over our 70-year history, The Leukemia & Lymphoma Society has been at the forefront of revolutionary cancer treatments from the early days of chemotherapy and stem cell transplantation to the leading edge discoveries of immunotherapy and precision medicine; our investment in research is nearly $1.3 billion over that time," said Lee Greenberger, LLS’s chief scientific officer. "With this new initiative, LLS maintains its role as a driver of innovation, supporting early stage research to propel discoveries that might lead to the next generation of treatments and cures, and help accelerate promising therapies to patients."

The grants are awarded to researchers seeking to understand the biological underpinnings of various blood cancers, what causes them to develop and grow, or become resistant to treatments. Each project will be supported by an award of $750,000 over a three-year period.

"In science, collaboration can accelerate the pace of achievement," said Michele Cleary, Ph.D., CEO of The Mark Foundation for Cancer Research. "Similarly, this three-way partnership among foundations will accelerate our understanding of cancer biology by empowering some of the brightest scientists to simultaneously probe unique but challenging areas of unmet need. We look forward to the discoveries that will result from these efforts."

Added Kathryn Richmond, Ph.D., MBA, director of the Frontiers Group, a division of the Allen Institute, "Our organization is committed to pushing the boundaries of bioscience and accelerating discoveries to make a difference for humankind, and we believe these grants will be a catalyst that will spark innovative new directions in blood cancer research."

"We are grateful that the Frontiers Group and Mark Foundation have aligned with us to fund some of the greatest minds in cancer discovery," said LLS’s Greenberger. "Collaborating with foundations who share a common goal of fueling leading-edge research to advance cures and better, safer treatments for cancer patients is critical to advancing our mission."

Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM)

On July 1, 2020 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, reported a development update for its XCART technology platform (Press release, Xenetic Biosciences, JUL 1, 2020, View Source [SID1234561619]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company entered into agreements with Scripps Research on May 19, 2020 and with PJSC Pharmsynthez on June 16, 2020 to advance the development of the XCART technology for B-cell malignancies. Both Scripps Research as well as Pharmsynthez and its collaborators have extensive experience with XCART, having co-invented the technology, and will have integral roles in the preclinical development activities.

"Our recently announced collaborations with Scripps Research, Pharmsynthez and multiple academic institutions in Russia and Belarus are critical components of our overall development plan for XCART. These agreements provide us access to partners that have the capability and capacity to expeditiously and cost-effectively advance XCART through preclinical development. We will also have access to patients and CART T clinical manufacturing suites which will potentially allow us to enter into a Phase 1 dosing study," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

The agreement with Scripps Research provides access to a team with extensive expertise in the CAR T space who will assist in the design and implementation of the preclinical development program for XCART. Xenetic will work with personnel in Dr. Richard Lerner’s lab, where the XCART technology was invented and where the preclinical proof of mechanism work was done. The agreement with Pharmsynthez provides access to the team that invented XCART in collaboration with Scripps Research, and also will involve institutions with extensive expertise in anti-idiotype approaches to lymphoma as well as CAR T development and manufacturing.

In collaboration with Pharmsynthez and multiple academic institutions in Russia and Belarus, the Company will conduct an exploratory trial to define and evaluate the XCART front-end process of target identification, screening and lead characterization in a real-world clinical setting. This exploratory stage entails enrollment of NHL patients, obtaining tumor biopsies and then refining the XCART front-end methods. Subsequently, the collaboration may be expanded to include development and qualification of manufacturing processes for producing autologous XCART T-cells. If successful, the Company has the potential to expand the clinical study component to dose a number of NHL patients in a Phase 1 dosing study. The data generated under the Belarus collaboration is expected to support an Investigational New Drug (IND) filing in the United States.

Curtis Lockshin, Ph.D., Chief Scientific Officer of Xenetic added, "As we move forward with these key partners, our team is focused on process development for autologous T cell manufacturing and generation of preclinical data covering the overall XCART workflow. These strategic collaborations provide us with highly cost-effective access to CAR T manufacturing and development suites, as well as clinical expertise and capabilities in the treatment of B-cell lymphomas. By augmenting preclinical data with insights gained from conduct of the XCART workflow in a human exploratory setting, we believe that we can strengthen the data sets with which we approach discussions with the United States Food and Drug Administration and, importantly, support our IND filing to advance our U.S. development strategy for XCART."

Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical

On July 1, 2020 Sumitomo Dainippon Pharma Oncology, Inc. reported that was formed today through the merger of Tolero Pharmaceuticals, Inc., and Boston Biomedical, Inc., two clinical-stage companies developing novel cancer therapeutics based in the U.S. and wholly owned subsidiaries of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology (Press release, Sumitomo Dainippon Pharma, JUL 1, 2020, View Source [SID1234561636]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Consolidation of the U.S. companies will combine both organizations’ passion, resources and expertise to advance science and research with the goal of bringing cancer therapies to market more rapidly. Through scientific persistence and a commitment to discovery, SDP Oncology is focused on advancing a diverse and purposeful pipeline that aims to positively impact outcomes for patients with cancer. The company’s areas of concentration will address unmet needs in oncology and encompass discovery research, external innovation, clinical development and commercialization.

"The merger of Tolero Pharmaceuticals and Boston Biomedical, and the formation of Sumitomo Dainippon Pharma Oncology, will help us achieve our vision of establishing oncology as a core driver of our business," said Hiroshi Nomura, Representative Director, Chief Executive Officer, Sumitomo Dainippon Pharma. "Over the last decade, these formerly separate organizations have expanded our oncology pipeline to include multiple advanced assets and early discovery programs. We look forward to furthering our commitment to oncology globally through the efforts of Sumitomo Dainippon Pharma Oncology."

Patricia S. Andrews has been appointed Chief Executive Officer and Global Head of Oncology. Andrews previously spent seven years at Boston Biomedical and served as Chief Executive Officer for the past three years. The global leadership team includes David Bearss, Ph.D., Chief Scientific Officer and Global Head of Research, Edgar Braendle, M.D., Ph.D., Chief Medical Officer and Global Head of Development, and Masashi Murata, Ph.D., Chief Strategy Officer, Global Strategy and Planning.

"The launch of this organization represents an exciting new beginning, bringing together distinct proficiencies and strengths from each geography into one collaborative team," said Patricia S. Andrews, CEO and Global Head of Oncology. "We operate in a unique position within the oncology landscape because we have the nimbleness of a small company combined with the support and resources of a global parent company. Working together, we strengthen our ability to embrace risks and bring forward meaningful cancer therapies that have the potential to truly advance the treatment landscape."

SDP Oncology’s discovery, research and development programs will span multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions. The company’s robust portfolio of preclinical and advanced-stage assets is currently being investigated in multiple solid tumors and hematologic malignancies, including metastatic colorectal cancer, glioblastoma, myelofibrosis and myelodysplastic syndrome. Augmenting this effort, SDP Oncology’s Global Oncology External Innovation Hub enhances collaboration with external organizations, such as academia and venture capital, to propel meaningful research in drug discovery for oncology.

The establishment of SDP Oncology will foster collaboration between colleagues across geographies from Utah to Massachusetts to Japan, encouraging innovation focused on bringing forward breakthrough therapies.

BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc.

On July 1, 2020 BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) reported that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer Inc. ("Pfizer") until the end of 2020 (Press release, BioInvent, JUL 1, 2020, View Source [SID1234561637]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In December 2016, the companies entered into the agreement for the development and commercialization of antibodies targeting tumor-associated myeloid cells discovered using BioInvent’s proprietary F.I.R.S.TTM drug discovery platform. The purpose of the research extension is to permit the companies to further identify and characterize new targets and antibodies binding to these targets.

In 2019 Pfizer selected the first and second target under the agreement, which triggered two payments from Pfizer to BioInvent of $300,000. BioInvent may be eligible for further milestone payments from development of antibodies directed against these targets as well as from the selection of additional targets and the development of antibodies directed against those targets.

Martin Welschof, CEO of BioInvent, said: "We are pleased to extend BioInvent’s long-running agreement with Pfizer which leverages our proprietary F.I.R.S.TTM technology platform and high-quality n-CoDeR antibody library. This extension provides Pfizer additional time to select optimal antibodies to their targets, as well as to explore more targets and corresponding antibodies. We look forward to continuing our successful collaboration with Pfizer."

Cambridge Spin-out PharmEnable Raises £1.8 million for Drug Discovery Expansion

On June 30, 2020 PharmEnable, a Cambridge-based drug discovery company using advanced medicinal chemistry and AI-enabled approaches to design the next generation of highly complex and specific drug candidate molecules, reported it has closed a £1.8 million seed financing to support its transition into a drug development company (Press release, PharmEnable, JUN 30, 2020, View Source [SID1234561564]). It aims to develop new treatments for conditions with significant unmet clinical need, by designing highly complex molecules for addressing challenging biological targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The round, which was significantly over-subscribed, was led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, as well as the University of Cambridge Enterprise Fund VI, managed by Parkwalk Advisors. It also attracted support from a wealth of angel investors and notable life science funds, including Jonathan Milner, serial entrepreneur and founder of Abcam; Andy Richards, Cambridge-based entrepreneur and investor; David Ford, Oxford-based life sciences angel investor; the family office of Paul Forster, co-founder of Indeed.com; Ian Tomlinson, chairman of several bio-incubators, entrepreneur and co- founder of Domantis; KQ Labs at the Francis Crick Institute; Martlet Capital, a Cambridge-based investor with a growing portfolio of innovative life science companies; the fast-growing o2h ventures Human Health EIS fund; and Wren Capital, the established London-based angel investor in science, engineering and software businesses.

A spin-out from the University of Cambridge in 2016, and financed to date by its founders and service-based revenues, PharmEnable will use the funding to evolve its business model and invest in a pipeline of drug discovery programmes across a number of disease areas including cancer and neurodegenerative disease. Additionally, PharmEnable will continue to engage in strategic partnerships with pharma, innovative biotechs and academia.

PharmEnable is led by co-founder and CEO Dr Hannah Sore. It has attracted an experienced Board and management team including Dr Jane Dancer, previously of F-star, who joined recently as the new Board Chair. The financing has enabled PharmEnable to expand its scientific team including Dr David Vidal as Director of Technology, with further expansion, including the addition of a Director of Drug Discovery planned for Q3 2020.

The PharmEnable platform technology can predict improved small molecule hits to targets across a range of disease areas. Its approach focuses on exploring and mapping the possible chemical universe and designing novel small molecules that are highly complex with shapes similar to those found in nature. This approach can identify hits with improved specificity compared with traditional screening methods, and allows PharmEnable to take on particularly challenging biological targets, such as protein-protein interactions and epitranscriptomic modifications that have been undruggable by existing approaches. Its solution consists of two elements: ChemUniverse a diversity-focused virtual database of chemically diverse molecules; and ChemSeek, a suite of gold standard AI-enabled tools for finding drug target matches from structure and ligand data.